"We are grateful for and proud of our accomplishments in our first full year as a public company, and remain on track to continue to hit our milestones in 2023 as we pursue our greater mission of democratizing health with our innovative vaccine technology," said Mei Mei Hu, CEO of Vaxxinity. "This year, we are poised to achieve our first potential marketing authorization as a company with UB-612, a heterologous booster vaccine candidate for COVID-19. We also expect to see two potential clinical proofs-of-concept in chronic disease in our migraine and hypercholesterolemia programs, and plan to complete Part B of our Phase 1 trial of UB-312 in Parkinson’s disease. At our new headquarters in Cape Canaveral, we are utilizing our state-of-the-art laboratory capabilities to further expand our platform and pipeline."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VAXX:
- Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
- Vaxxinity joins TransCelerate Research and Development Consortium
- Vaxxinity Joins TransCelerate Research and Development Consortium
- Vaxxinity announces first subjects dosed in Phase 1 trial of VXX-401
- Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia